Absorption & A2M Activation

The proteases specifically chosen for inclusion in the pHysioProtease® blend are highly resistant to gastric acidity which allows them, when taken between meals, to pass through the acidity of the stomach unharmed and be absorbed intact from the small intestines into the bloodstream.[11-14] These proteases are immediately attached to circulating alpha-2-macroglobulins to keep the enzymes from stimulating an immune response, which occurs when an unshielded foreign protein enters the blood.[15,16] This protease attachment results in a conformational change in the macroglobulin, increasing its activity and mobility to sites of inflammation throughout the body.[17,18] Research suggests this activation of alpha-2-macroglobulins by the type of proteases found in pHysioProtease® is the mechanism by which these supplemental proteolytic enzymes quickly and effectively modulate the inflammatory cascade.[19]* This patented mechanism for increasing activated alpha-2-macroglobulins in the plasma and interstitial fluids (US patent 6,413,512) emphasizes the importance of using systemic proteases with optimal activity in the physiological conditions of the blood and tissue fluid of the body.[20]

Cardiovascular Maintenance

Studies have shown supplemental proteases including those found in pHysioProtease® can have a positive effect on the flow characteristics of blood by supporting normal fibrinolytic activity, red blood cell flexibility and vessel wall integrity.[46-49]* Better blood flow assures adequate oxygen, nutrients and fibroblasts are transported to damaged tissue for use in the healing process.

Immune Support

Alpha-2-macroglobulins activated by protease increase macrophage and other phagocytic activity which helps the body break down and eliminate cellular debris and many harmful agents such as microorganisms, allergens, chemicals and rogue cells.[25] The complement system, an integral component of innate immunity, receives assistance from protease-activated alpha-2-macroglobulins in the degradation of inflammation-causing immune complexes circulating in the blood and those deposited in soft tissues.[34-38] Research further shows these active macroglobulins facilitate the clearance of protein damaged by heat or oxidation preventing an accumulation of abnormal proteins in the body with the potential to form destructive amyloids.[39-41] This cleansing or detoxification of the blood, lymph and tissue fluid is an important way pHysioProtease® can enhance the body’s immune response and quality of life.[42-45] *

Inflammation Management

Protease-activated alpha-2-macroglobulins bind to pro-inflammatory cytokines including TNF-alpha and IL-1 beta, facilitating their rapid clearance through the liver, as well as to anti-inflammatory cytokines such as TGF-beta, assisting in their stimulation of tissue repair.[21-23] These activated macroglobulins have also been found to help control the presence of other pro-inflammatory mediators, especially kinins and prostaglandins, in damaged tissue which may result in less pain, reduced edema and faster recovery.[7, 24-28] The modulating effect of supplemental proteases like pHysioProtease® on inflammation is further supported by studies showing activated alpha-2-macroglobulins can slow the migration of neutrophils to sites of tissue damage or deterioration as well as enhance the activity of macrophages and natural killer cells.[29-33]*


  1. Muhammad ZA, Ahmad T. Therapeutic uses of pineapple-extracted bromelain in surgical care – A review. J Pak Med Assoc. 2017 Jan;67(1):121-125.
  2. Varayil MD JE, MD; Bauer MD BA, Hurt MD, PhD RT. Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know. Mayo Clin Proc. September 2014; 89(9):1307-1312.
  3. Kolac C., Streichhan P., Lehr CM. Oral bioavailability of proteolytic enzymes. European Journal of Pharmaceutics and Biopharmaceutics. 1996, vol. 42, no4, pp. 222-232.
  4. Ambrus JL, et al.: Absorption of exogenous and endogenous proteolytic enzymes. Clin Pharmacol Therap 1967;8:362-8.
  5. Castell, J.V.; Friedrich, G.; Kuhn, C.S.; Poppe, G.E. “Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake”. Am J Physiol 1997; 273: G139-G146.
  6. Nouza K, Wald M. Systemic enzyme therapy: problems of resorption of enzyme macromolecules. Cas Lek Cesk 1995; 134 (19):615-9.
  7. Borth W Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992 Dec;6(15):3345-53.
  8. Garzone, PD. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules. Principles of Clinical Pharmacology 2nd ed.: 479-500.
  9. Nouza K. Outlooks of systemic enzymes therapy in rheumatoid arthritis and other immunopathological diseases. Acta Univ Carol [Med] (Praha). 1994;40(1-4):101-4.
  10. Larsson, L.J.; Frisch, E.P.; Torneke, K.; Lindblom, T. & Bjork, I. “Properties of the complex between alpha 2-macroglobulin and brinase, a proteinase from Aspergillus oryzae with thrombolytic effect”. Thromb Res 1988; 49: 55-68.
  11. Houston DB, Greaves LS, Andrews LD, Collier AW. Composition and Method for Treating Disease by Increasing Activated Alpha-2-Macroglobulin in the Blood and Extravascular Tissue. US patent 6,413,512. 1999.
  12. LaMarre J et al. Cytokine binding and clearance properties of proteinase-activated alpha- 2-macroglobulins. Lab Invest. 1991;65(1):3-14.
  13. Rehman AAAhsan HKhan FH. Alpha-2-Macroglobulin: a physiological guardian. J Cell Physiol.2013 Aug;228(8):1665-75.
  14. Eming, SA, Krieg T, Davidson JM. Inflammation in Wound Repair: Molecular and Cellular Mechanisms. Journal of Investigative Dermatology. March 2007. 127(3):514-525.
  15. van Gool J , van Vugt H, de Bont E. Alpha 2-macroglobulin and fibrinogen modulate inflammatory edema in man. Inflammation. 1990 Jun;14(3):275-83.
  16. Rathnavelu V, al. Potential role of bromelain in clinical and therapeutic applications. Biomed Rep. 2016 Sep; 5(3): 283–288.
  17. Brown SA, Coimbra M, Coberly DM, Chao JJ, Rohrich RJ. Oral Nutritional Supplementation Accelerates Skin Wound Healing: A Randomized, Placebo-Controlled, Double-Arm, Crossover Study. Plastic & Reconstructive Surgery. July 2004. 114(1):237-244.
  18. Kerkhoffs Gm et al. A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic Br J Sports Med. 2004 Aug; 38(4) :431-5.
  19. Klein G, Kullich W. Reducing pain by oral enzyme therapy in rheumatic diseases. Wien Med Wochenschr. 1999;149:57780.
  20. Forrester JV,  Wilkinson PC, Lackie Effect of modified alpha 2 macroglobulin on leucocyte locomotion and chemotaxis. Immunology. 1983 Oct; 50(2): 251–259.
  21. Fitzhugh DJ1, Shan S, Dewhirst MW, Hale LP. “Bromelain treatment decreases neutrophil migration to sites of inflammation.” Clin Immunol. 2008 Jul;128(1):66-74.
  22. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol. 2002;104:183–190. 
  23. Misra UKSharma TPizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin: activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol.2005 Aug 15;175(4):2525-33.
  24. Stauder G. Pharmacological effects of oral enzyme combinations. Cas Lek Cesk. 1995 Oct 4;134(19):620-4.
  25. Steffen CMenzel J. Enzyme breakdown of immune complexes. Z Rheumatol.1983 Sep-Oct;42(5):249-55.
  26. Nakazawa M. et al. Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. J Exp Med. 1986;164(6):1973-87.
  27. Gesualdo L. et al. Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria and mesangial proliferation in murine experimental IgA nephropathy. J Clin Invest. 1990;80:715-22.
  28. Steffen C et al.: Enzyme therapy in comparison with immune complex determinations in chronic polyarteritis. Rheumatologie 1985;44:51-6.
  29. Stauder G et al. The use of hydrolytic enzymes as adjuvant therapy in AIDS/ARC/LAS patients. Biomed Pharmacother. 1988;42(1):31-4.
  30. Wyatt AR et. al. Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett. 2013 Mar 1; 587(5): 398–403.
  31. French K, Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin modulates a chaperonelike action with broad specificity. Biochemistry. 2008 Jan 29;47(4):1176-85.
  32. Lauer DReichenbach ABirkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1–42: a mechanism to enhance amyloid beta catabolism. Exp Neurol.2001 Feb;167(2):385-92.
  33. Beuth J. “Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction?” Integr Cancer Ther. 2008 Dec;7(4):311-6.
  34. Popiela T et al. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers-an epidemiological retrolective cohort study. Cancer Chemother Pharmacol. 2001;47:S55-63.
  35. Leipner J, Saller R: Systemic enzyme therapy in oncology: effect and mode of action. Drugs. 2000;59:769-80.
  36. Arazi A1, Neumann AU. “Modeling immune complex-mediated autoimmune inflammation.” J Theor Biol. 2010 Dec 7;267(3):426-36.
  37. Nouza K. Systemic enzyme therapy in diseases of the vascular system. Bratisl Lek Listy. 1995 Oct;96(10):566-9.
  38. Pavan R, Jain S, Shraddha, Kumar A. Properties and Therapeutic Application of Bromelain: A Review. Biotechnology Research International. 2012;2012:976203.
  39. Ley CM et al. A review of the use of bromelain in cardiovascular diseases. J of Chinese Integrative Medicine. July 2011. 9(7):702-709.
  40. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application: an update. J Ethnopharmacol. 1988;22(2):191-203.